Piper Sandler lowered the firm’s price target on Myriad Genetics (MYGN) to $11.50 from $14 following quarterly results. The firm keeps a ...

In a report released today, David Westenberg from Piper Sandler maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P.

New York State Common Retirement Fund boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a ...

Paul J. Diaz, President and CEO of Myriad, adds "PATHOMIQ's technology platform, together with Myriad's infrastructure and ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...

Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.